In a report released today, Caroline Palomeque from Maxim Group maintained a Buy rating on AzurRx BioPharma Inc (AZRX), with a price target of $5. The company’s shares closed yesterday at $1.70.
Palomeque commented:
“AzurRx announced that it has dosed the first patients of its Phase 2 OPTION trial (N=30) of MS1819-SD in exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF).”
According to TipRanks.com, Palomeque ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -13.3% and a 34.1% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as VistaGen Therapeutics, Anavex Life Sciences, and Oxford BioMedica plc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AzurRx BioPharma Inc with a $6.33 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.75 and a one-year low of $1. Currently, AzurRx BioPharma Inc has an average volume of 79.37K.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AZRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AzurRx BioPharma, Inc. is a development stage company, which engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. It offers MS1819 and AZX1101 that are therapeutic proteins products under development. The company was founded on January 30, 2014 and is headquartered in Brooklyn, NY.
